Welcome to our dedicated page for HilleVax SEC filings (Ticker: HLVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HilleVax, Inc. (HLVX) SEC filings page on Stock Titan provides access to the company’s historical regulatory documents, including Forms 10-K, 10-Q, 8-K, 25 and 15, as filed with the U.S. Securities and Exchange Commission. These filings document HilleVax’s period as a Nasdaq-listed clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, particularly virus-like particle (VLP) based candidates such as HIL-214 and HIL-216 for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Investors and analysts can use periodic reports like annual reports on Form 10-K and quarterly reports on Form 10-Q to review HilleVax’s historical financial statements, research and development spending, general and administrative expenses, and risk factor disclosures related to its norovirus vaccine programs. Current reports on Form 8-K capture material events, including announcements about clinical trial results, workforce reductions, strategic reviews, and the agreement and plan of merger with XOMA Royalty Corporation.
Filings in 2025 are particularly important for understanding the corporate transaction and change in listing status. A Form 8-K dated September 17, 2025, describes the completion of the tender offer and merger in which HilleVax became a wholly owned subsidiary of XOMA Royalty. A Form 25 filed on September 17, 2025, by The Nasdaq Stock Market LLC provides notification of the removal of HilleVax’s common stock from listing and registration under Section 12(b) of the Exchange Act. A subsequent Form 15 filed on September 29, 2025, certifies the termination of registration of the common stock under Section 12(g) and the suspension of HilleVax’s duty to file reports under Sections 13 and 15(d).
On Stock Titan, users can view these documents in sequence and rely on AI-powered summaries that highlight key points from lengthy filings, such as the terms of the merger, the structure of the contingent value right, and the implications of delisting and deregistration. This makes it easier to interpret how HilleVax’s regulatory history reflects its evolution from a standalone public issuer to a subsidiary of XOMA Royalty, and how its norovirus vaccine programs were described in official SEC disclosures.
HilleVax, Inc. (HLVX) filed a Form 4 reporting that director Nanette Cocero received a grant of 17,199 Restricted Stock Units (RSUs) on 23-Jun-2025 under the company’s 2022 Incentive Award Plan. The grant was made at $0.00 cost and represents the reporting person’s entire beneficial ownership in HLVX common stock following the transaction. All RSUs will vest 100 % on the earlier of (i) the first anniversary of the grant date or (ii) a Change in Control, provided the director remains on the board through that date. No open-market purchases, sales, or derivative transactions were reported, and ownership is held directly.
On June 23, 2025, HilleVax, Inc. (HLVX) director Julie L. Gerberding filed a Form 4 disclosing receipt of 17,199 Restricted Stock Units (RSUs) granted under the company’s Non-Employee Director Compensation Program. The award vests 100 % on the earlier of the first anniversary of the grant date or a defined Change in Control, contingent upon her continued board service. The RSUs were issued at $0.00 cost, indicating a non-cash, equity-based compensation item. Following the grant, Gerberding’s direct beneficial ownership rose to 59,224 common shares. No sales, option exercises, or other derivative transactions were reported.
HilleVax, Inc. (HLVX) – Form 4 filing dated 25-Jun-2025
Non-employee director Gary Dubin was granted 17,199 Restricted Stock Units (RSUs) on 23-Jun-2025 under HilleVax’s 2022 Incentive Award Plan and director compensation program. The RSUs were reported as an "A" (acquired) transaction at a cost basis of $0.00, increasing Dubin’s directly-held beneficial ownership to 17,199 common shares. Vesting is single-tranche: 100% on the earlier of (i) the first anniversary of grant or (ii) a Change in Control, contingent on continued board service. No derivative securities, sales, or additional purchases were disclosed.
The transaction represents routine annual equity compensation rather than an open-market purchase and therefore has limited immediate valuation impact. However, the grant modestly aligns director incentives with shareholder value and signals no insider selling.
HilleVax, Inc. filed a Form 8-K to report the results of its 23 June 2025 Annual Meeting of Stockholders. Two routine governance items were presented:
- Election of three Class III directors – Robert Hershberg, Jeryl Hilleman and Aditya Kohli were each re-elected for three-year terms, receiving roughly 22.0-22.4 million votes for and 1.5-1.8 million votes withheld; 14.5 million broker non-votes were recorded.
- Ratification of auditor – Ernst & Young LLP was confirmed as the Company’s independent registered public accounting firm for fiscal 2025 with 38.24 million votes for, 0.13 million against and 8,105 abstentions.
No other business or financial information was disclosed. The filing indicates normal, uncontested corporate governance with shareholder support for both board composition and external audit appointment.